All In Biotech

Drug Trial Radar · NCT00531596

Evaluation of Adhesion and Dermal Tolerability of EMSAM

A PHASE IV, OPEN-LABEL STUDY OF THE ADHESION AND DERMAL TOLERABILITY OF EMSAM (SELEGILINE TRANSDERMAL SYSTEM) IN HEALTHY ADULT SUBJECTS OF TWO AGE GROUPS (18 - 64 YEARS, AND 65 YEARS AND OLDER)

Last checked: Nov 20, 2026Latest source record: Sep 19, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Apr 2007

Primary completion

Not stated

Study completion Jul 2007

Sponsor

Lead sponsor
Somerset PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
None
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Examine adhesive and dermal tolerability of EMSAm 6mg/24hr and 12mg/24hr in healthy elderly and non-elderly subjects.

Conditions

  • Healthy

Interventions

  • EMSAM (Selegiline Transdermal System) 6mg/24HrDrug

    EMSAM 6mg/24HR

  • EMSAM (Selegiline Transdermal System) 9mg/24HrDrug

    EMSAM 9mg/24Hr

  • EMSAM (Selegiline Transdermal System) 12mg/24hrDrug

    EMSAM 12mg/24Hr

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adhesion characteristics and dermal tolerability (irritation) of EMSAM in two populations consisting of non-elderly (18 - 64 years) and elderly (65 years and older) healthy volunteers.Time frame: 21 Days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hill Top Research

    Scottsdale, Arizona

  • Hill Top Research

    St. Petersburg, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.